**e-table 7. Certainty of the evidence (GRADE) Profile at Outcome Level**

|  |
| --- |
| **Patient or population: COVID-19** **Intervention: Ivermectin** **Comparison: No Ivermectin** |
| 1. **GRADE for Mortality**
 |
| Outcomes | **Anticipated absolute effects\*** (95% CI) | Relative effect(95% CI) | № of participants (studies) | Certainty of the evidence(GRADE) | Comments |
| **Risk with No Ivermectin** | **Risk with Ivermectin** |
| **Mortality (Overall)** | 143 per 1,000 | **83 per 1,000****(54 to 126)** | **OR 0.54****(0.34 to 0.86)** | 12647(29 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| **Mortality (Clinical trials)** | 75 per 1,000 | **37 per 1,000****(20 to 68)** | **OR 0.47****(0.25 to 0.90)** | 3592(18 studies) | ⨁⨁◯◯LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| **Mortality (Therapeutic RCTs Mild-Moderate COVID-19)** | 24 per 1,000 | **8 per 1,000****(2 to 25)** | **OR 0.31****(0.09 to 1.04)** | 2261(12 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin and upgraded for very large magnitude of effect |
| **Mortality (Therapeutic RCTs Severe/Critical COVID-19)** | 200 per 1,000 | **177 per 1,000****(113 to 266)** | **OR 0.86****(0.51 to 1.45)** | 410(6 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin |
| **Mortality (Observational)** | 158 per 1,000 | **107 per 1,000**(62 to 179) | **OR 0.64**(0.35 to 1.16) | 9055(11 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| **Mortality (Inpatient Overall)** | 158 per 1,000 | **109 per 1,000****(73 to 158)** | **OR 0.65****(0.42 to 1.00)** | 9825(18 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| **Mortality (Inpatient RCTs-Severe/Critical COVID-19)** | 65 per 1,000 | **12 per 1,000****(1 to 80)** | **OR 0.18****(0.02 to 1.25)** | 645(5 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias and inconsistency and upgraded for large magnitude of effect |
| **Mortality (Inpatient RCTs- Mild-Moderate COVID-19)** | 200 per 1,000 | **177 per 1,000****(113 to 266)** | **OR 0.86****(0.51 to 1.45)** | 410(6 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias and inconsistency and upgraded for large magnitude of effect |
| **Mortality (Observational Inpatient)** | 162 per 1,000 | **119 per 1,000**(68 to 200) | **OR 0.70**(0.38 to 1.30) | 8683(8 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| **Mortality (Effect of Ivermectin Monotherapy as per Cochrane Guideline with Placebo/Standard of Care RCTs: Overall** | 26 per 1,000 | 20 per 1,000 | **OR 0.75****(0.35 to 1.63)** | 1424(7 studies) | ⨁⨁⨁◯MODERATE | Downgraded for risk of bias and inconsistency and upgraded for large magnitude of effect and study design |
| **Mortality (Effect of Ivermectin alone as per Cochrane Guideline with Placebo/Standard of Care RCTs: Mild-Moderate COVID-19)** | 18 per 1,000 | **13 per 1,000****(5 to 34)** | **OR 0.71****(0.27 to 1.87)** | 1351(6 studies) | ⨁⨁⨁◯MODERATE | Downgraded for risk of bias and inconsistency and upgraded for large magnitude of effect and study design |
| **Mortality (Effect of Ivermectin alone as per Cochrane Guideline with Placebo/Standard of Care RCTs- Severe/Critical COVID-19)** | 162 per 1,000 | **138 per 1,000****(4**3 **to 3**6**9)** | **OR 0.83****(0.23 to 3.02)** | 73(1 study) | ⨁⨁◯◯LOW | Downgraded for risk of bias, small sample size and inconsistency and upgraded for study design |
| 1. **GRADE for ICU admission**
 |
| **Need for ICU Admission** | 161 per 1,000 | **85 per 1,000**(32 to 209) | **OR 0.48**(0.17 to 1.37) | 585(5 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias and inconsistency |
| 1. **GRADE for Mechanical Ventilation**
 |
| **Need for Mechanical Ventilation** | 76 per 1,000 | **58 per 1,000**(41 to 82) | **OR 0.75**(0.52 to 1.08) | 2516(12 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, and publication bias |
| 1. **GRADE for Adverse events**
 |
| **Adverse Event** | 210 per 1,000 | **188 per 1,000**(151 to 231) | **OR 0.87**(0.67 to 1.13) | 2777(22 studies) | ⨁◯◯◯VERY LOW | Downgraded for study design, risk of bias, inconsistency, imprecision, and publication bias |
| 1. **Need for Hospitalization**
 |
| **Need for Hospitalization** | 224 per 1,000 | **89 per 1,000(44 to 178)** | **OR 0.34(0.16 to 0.75)** | 2021(6 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin and upgraded for very large magnitude of effect |
| 1. **Duration of Hospital Stay**
 |
| **Duration of Hospital stay** | The mean duration of Hospital stay was **0** | MD **1.8 lower**(3.69 lower to 0.08 higher) | **-** | 1246(9 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin and upgraded for very large magnitude of effect |
| 1. **Incidence of Viral Clearance**
 |
| **Incidence of Viral clearance** | 655 per 1,000 | **870 per 1,000**(775 to 929) | **OR 3.52**(1.81 to 6.86) | 2533(22 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin and upgraded for very large magnitude of effect |
| 1. **Time to Achieve Viral Clearance**
 |
| **Time to Achieve Viral Clearance** | The mean time to achieve Viral clearance was **0** | MD **4.12 lower**(7.59 lower to 0.65 lower) | **-** | 948(8 studies) | ⨁⨁◯◯LOW | Downgraded for risk of bias, mixed effect of Ivermectin and upgraded for very large magnitude of effect |
| **\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).****CI: Confidence interval; MD: Mean difference** |
| **GRADE Working Group grades of evidence****High certainty: We are very confident that the true effect lies close to that of the estimate of the effect****Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different****Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect****Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect** |